News | June 11, 2009

PETNET Signs Supply Deal with Lantheus for Cardiac Perfusion Trials

June 11, 2009 – PETNET Solutions, a subsidiary of Siemens Medical Solutions USA Inc. that manufactures and distributes radiopharmaceuticals, has signed a supply agreement with Lantheus Medical Imaging Inc. to provide BMS747158 for PET imaging of cardiac perfusion as part of the phase II and phase III trials.

PETNET Solutions/Siemens has previously supplied all of the clinical trial doses for the Lantheus Phase I study. BMS747158 is Lantheus’ novel fluorine 18-labeled positron emission tomography (PET) tracer for myocardial perfusion imaging in subjects under rest and stress conditions.
 
PETNET Solutions is committed to advancing molecular imaging by support of clinical trials.
 
“Our agreement with Lantheus further emphasizes PETNET’s network as an attractive channel for novel PET agents,” said Tom Welch, chief executive officer of PETNET Solutions. “We are proud to be involved with BMS747158 as one of the many important R&D projects that Siemens is actively engaged in.”
 
PETNET Solutions operates the largest PET radiopharmacy network with 52 radiopharmacies and distribution centers worldwide that manufacture and distribute PET biomarkers to hospitals, clinics, and research facilities for PET imaging. 

For more information: www.siemens.com/healthcare.
 

Related Content

Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...